Trevena Inc. (TRVN) 6.91 $TRVN Trevena CEO to present at

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Trevena Inc. (TRVN) 6.91 $TRVN

Trevena CEO to present at the 14th Annual Needham Healthcare Conference
Business Wire - Wed Apr 08, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 10:00 a.m. EDT in New York.
TRVN: 6.91 (-0.53)

Nasdaq stocks posting largest percentage increases
AP - Thu Apr 02, 5:09PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
EGLE: 8.55 (+0.05), IMDZ: 26.66 (+0.22), TRVN: 6.91 (-0.53), BCRX: 10.62 (-0.09), ARCW: 7.06 (-0.57), ARWR: 6.88 (+0.14), ASPS: 18.07 (+1.32), EGRX: 60.53 (+1.22), DYAX: 28.12 (+0.15), VBFC: 19.86 (-0.12), SQBG: 13.46 (-0.54), RDI: 13.82 (+0.28), DGLY: 13.13 (+0.08), RDIB: 13.04 (-0.36)

Healthcare ratings round up
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 12:23PM CDT

OXGN: 1.49 (-0.02), TRVN: 6.91 (-0.53), ESPR: 100.53 (-2.60), OVAS: 29.85 (-0.24), UHS: 121.07 (+0.12), NLNK: 53.12 (-0.07), RTRX: 24.45 (+0.09), SYK: 96.45 (+1.74)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 11:49AM CDT

TRVN: 6.91 (-0.53), WGO: 20.92 (-0.21), CCSC: 5.36 (-0.04), OTIV: 1.58 (+0.03), DPLO: 34.52 (+0.26), CNAT: 6.31 (-0.15), WGBS: 4.66 (-0.08), HKTV: 7.67 (-0.33), DVD: 2.34 (-0.02), SEDG: 23.81 (+0.13), ENVA: 19.54 (+0.31), SEED: 1.66 (+0.05), RHT: 75.76 (+0.54), SCMP: 21.75 (+0.47), SGNT: 25.43 (-0.29), WRLD: 74.99 (+0.21), VBLT: 4.37 (-0.08), RCON: 1.87 (-0.04), SNDK: 68.48 (+0.56)

Insiders Seeing Green With TRVN At New 52-Week High
MarketNewsVideo.com - Tue Mar 24, 12:11PM CDT
In trading on Tuesday, shares of Trevena Inc touched a new 52-week high of $8.16/share. That's a 114.74% rise, or $4.36 per share from the 52-week low of $3.80 set back on 12/09/2014.
TRVN: 6.91 (-0.53)

Trevena's Q4 2014 Results Conference Call - What We Learned
Scrying Biotech - at Seeking Alpha - Mon Mar 23, 12:14PM CDT

TRVN: 6.91 (-0.53), ACT: 295.22 (+0.69)

Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.91 (-0.53), MDT: 78.01 (+0.93), CLDX: 28.95 (+1.08), FOMX: 10.94 (-0.02), AMGN: 169.10 (+0.64), AET: 107.95 (-0.41), NKTR: 10.90 (+0.16), CELG: 115.54 (+0.72), HUM: 180.01 (-0.12), CANF: 2.12 (+0.17), ANTM: 152.84 (-0.04), NVO: 56.37 (-0.17), GILD: 104.18 (-1.02), GERN: 4.20 (-0.04), AZN: 73.35 (+0.65), CLLS: 31.30 (-0.91), WCG: 82.65 (-0.33), FOLD: 11.97 (-0.35), REGN: 472.63 (+9.41), CUR: 1.96 (-0.04)

Trevena CMO to Present at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference
Business Wire - Wed Mar 18, 3:30PM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced David Soergel, M.D., its chief medical officer, will present a company overview at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference on Friday March 20, 2015 at 3:00 p.m. EDT in New York.
TRVN: 6.91 (-0.53)

Trevena's (TRVN) CEO Max Gowen on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 18, 12:46PM CDT

TRVN: 6.91 (-0.53)

Trevena FY14 results
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 7:53AM CDT

TRVN: 6.91 (-0.53)

Trevena reports 4Q loss
Automated Insights - Wed Mar 18, 6:18AM CDT
KING OF PRUSSIA, Pa. (AP) _ Trevena Inc. (TRVN) on Wednesday reported a loss of $13.3 million in its fourth quarter.
TRVN: 6.91 (-0.53)

Trevena beats by $0.07
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 6:03AM CDT

TRVN: 6.91 (-0.53)

Trevena Reports Full Year 2014 Financial Results
Business Wire - Wed Mar 18, 6:00AM CDT
--- Phase 2b BLAST-AHF Trial of TRV027 in Acute Heart Failure Expanded -
TRVN: 6.91 (-0.53)

Trevena Inc: Profitable To You And Disruptive To Everyone Else
Scrying Biotech - at Seeking Alpha - Mon Mar 16, 5:31PM CDT

TRVN: 6.91 (-0.53), ACT: 295.22 (+0.69)

Trevena to Host Conference Call on March 18th to Discuss Full Year 2014 Financial Results
Business Wire - Wed Mar 11, 6:00AM CDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced that it will host a conference call on Wednesday, March 18, 2015 at 8:30 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2014.
TRVN: 6.91 (-0.53)

Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure
Business Wire - Mon Mar 09, 6:00AM CDT
--- Actavis fully funds expansion of study -
TRVN: 6.91 (-0.53)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 356

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 371

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 150

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 347

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Retirement Dreams Dashed: 61% Withdraw Early

Updated Category News Views 309

Retirement Caught in the Crosshairs Just when you think the path to retirement might clear up, life slaps down older workers with economic reality. A recent LiveCareer survey underscores this financial mess, revealing that 61% of those 50 and older are raiding their own retirement funds to make ends meet. It's enough to make one's head spin. Inflation: The Unwanted Guest...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 238

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 177

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 433

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 243

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading

Top 5 Most Recently Viewed Articles

Air Canada Navigates Operational Challenges Amid Storms

Updated Category News Views 205

Air Canada's Operational Challenges and Responses Air Canada has recently faced significant operational hurdles due to severe winter weather and an aircraft incident impacting its Toronto Pearson international hub. These challenges have necessitated a comprehensive update from the airline about its current status and ongoing recovery efforts. Recent Weather Impact on...

Continue Reading
Insight into Melexis' Ongoing Share Buy-Back Strategy

Updated Category News Views 128

Melexis Enhances Shareholder Value Through a Strategic Buyback Melexis, a leader in the semiconductor industry, has been actively engaging in a strategic share buy-back program aimed at bolstering shareholder value. This initiative, first announced on December 10, 2024, reflects the company's commitment to enhancing its stock's performance while also optimizing its...

Continue Reading
Value Line, Inc. Launches New Share Repurchase Initiative

Updated Category News Views 220

Value Line, Inc. Announces Stock Repurchase Program Value Line, Inc. (NASDAQ: VALU) recently revealed an exciting development for its shareholders: the Board of Directors has approved a share repurchase program that allows for the buyback of up to $2,000,000 worth of shares. This program comes into effect immediately and marks a significant move that replaces the previous...

Continue Reading
IsoEnergy Expands Stake in Premier American Uranium Inc. Assets

Updated Category News Views 154

IsoEnergy Enhances Investment in Premier American Uranium Inc. IsoEnergy Ltd. (NYSE American: ISOU) (TSX: ISO) has recently expanded its investment in Premier American Uranium Inc. by acquiring a significant number of common shares and warrants. This strategic move further establishes IsoEnergy’s commitment to capitalizing on the promising uranium market amid increasing...

Continue Reading
Texas Attorney General Takes Action Against Insulin Price Fixing

Updated Category News Views 70

Texas Attorney General's Lawsuit Against Insulin Price Fixing Texas Attorney General Ken Paxton has taken significant action by filing a lawsuit against several prominent insulin manufacturers and pharmacy benefit managers (PBMs). The lawsuit highlights allegations of a conspiracy to inflate insulin prices, affecting countless patients who rely on this vital medication....

Continue Reading